HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.

By FierceBiotech · Apr 21, 2026 · via FierceBiotech
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B

Image: FierceBiotech

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Asahi Kasei acquires German company Aicuris
DealsPharmaceutical Technology ↗
Asahi Kasei acquires German company Aicuris
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.…
Apr 21, 2026
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
DealsEndpoints News ↗
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in ce…
Apr 20, 2026
Lilly Bets $3.25B on Kelonia to Push In‑Vivo CAR‑T from Concept to Platform
Deals
Lilly Bets $3.25B on Kelonia to Push In‑Vivo CAR‑T from Concept to Platform
Lilly’s $3.25 billion upfront acquisition of Kelonia Therapeutics signals a bold move into in‑vivo CAR‑T techn…
Apr 20, 2026